---
title: "Gossamer Bio climbs 2% as Leerink upgrades to Outperform"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294098875.md"
description: "Gossamer Bio rises 2% in regular trading after Leerink Partners upgrades rating to Outperform."
datetime: "2026-07-28T17:50:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294098875.md)
  - [en](https://longbridge.com/en/news/294098875.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294098875.md)
generator: "portal-rs"
---

# Gossamer Bio climbs 2% as Leerink upgrades to Outperform

Gossamer Bio(GOSS.US) 盘中涨**2.11%**，现报**0.2036 美元**。

Leerink Partners 将该股评级上调至 Outperform，推动股价上涨。

### Related Stocks

- [GOSS.US](https://longbridge.com/en/quote/GOSS.US.md)

## Related News & Research

- [Gossamer Bio to Present at Cantor Global Healthcare Conference | GOSS Stock News](https://longbridge.com/en/news/298036471.md)
- [Gossamer Bio cuts shareholder meeting quorum requirement to one-third of voting power](https://longbridge.com/en/news/297952332.md)
- [Gossamer Bio announces special shareholder meeting via webcast](https://longbridge.com/en/news/297952610.md)
- [Gossamer Bio Restructures Debt, Secures Full Control of Lead Drug Candidate](https://longbridge.com/en/news/293964802.md)
- [Gossamer Bio announces $250m in funding to advance seralutinib](https://longbridge.com/en/news/296771347.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**